Title: Use of Nicotine Products, Prescription Drug Products, and Other Methods to Stop Smoking by US Adults in the 2022 National Health Interview Survey

Authors: Floe Foxon[1]; Raymond Niaura[2]

Affiliations:

[1]Department of Data Management and Statistical Analysis, Pinney Associates, Pittsburgh, Pennsylvania, United States of America.

[2]Department of Social and Behavioral Sciences, School of Global Public Health, New York University, New York, New York, United States of America.

Corresponding Author: Floe Foxon (ffoxon@pinneyassociates.com)

ORCiDs

Floe Foxon: 0000-0002-4893-9178

Raymond Niaura: 0000-0002-0856-3540

Abstract

Recent data on methods used by adults to stop smoking can inform tobacco control policies. Nationally representative Centers for Disease Control and Prevention survey data from the 2022 National Health Interview Survey (N=27,651) were used to analyze populations of US adults who self-reported having stopped smoking cigarettes for 6 months or longer in the last year and the methods they used, or who did not stop smoking but tried in the last year (n=1,735). In 2022, an estimated 2.9 million [95% CI:2.5 million–3.2 million] US adults had stopped smoking in the past year. Most were male, non-Hispanic White, aged <55 years, college-educated, identified as straight, were not depressed, and currently drank alcohol. The most popular methods used to stop smoking were nicotine products (53.9% [47.4%–60.3%]; 1.5 [1.3–1.8] million adults), especially e-cigarettes in combination with other methods (40.8% [34.4%–47.5%]; 1.2 [0.9–1.4] million) and e-cigarettes alone (26.0% [20.4%–32.3%]; 0.7 [0.6–0.9] million). Prescription drug products (8.1% [5.3%–11.8%]; 0.2 [0.1–0.3] million) and non-nicotine, non-prescription drug methods (6.3% (3.9%–9.7%); 0.2 [0.1–0.3] million) were less popular. A further 13.1 [12.2–14.0] million tried but did not stop smoking. Compared to those who tried but didn't stop smoking, those who successfully stopped were more likely to be younger, degree-educated, and to use e-cigarettes to stop smoking. Many adults still attempt to stop smoking unaided. Interventions to reduce smoking could focus on populations that stopped smoking the least and encourage use of evidence-based methods.

Keywords: Smoking Cessation; Pharmacotherapy; E-Cigarettes; Nicotine Replacement Therapy; Counseling; Quit Methods

Introduction

Although considerable progress has been made in the last decade in the US to reduce prevalence of combustible cigarette smoking [1], smoking continues as one of the leading causes of chronic disease [2]. Thus, further reductions in smoking prevalence are crucial to preventing or reducing the effects of chronic disease in the US. A previous study using data from the Population Assessment of Tobacco and Health (PATH) Study found that unaided quit attempts were the most common methods used by US adults to stop smoking from 2013 through 2014 accounting for almost half of quit attempts, with the most frequently used single methods being help from friends and family followed by use of e-cigarettes [3]. Another study found that giving up cigarettes all at once (65.3% of people who smoke and tried to quit), gradually cutting back on cigarettes (62.0%), and substituting some cigarettes with e-cigarettes (35.3%) as the most commonly reported stop-smoking methods during quit attempts from 2014 through 2016 [4]. More recent data are needed to understand who stopped smoking since 2016 and how they did it, particularly with respect to novel nicotine products such as e-cigarettes undergoing FDA review to determine whether or not they may be considered "appropriate for the protection of public health" (e.g. see [5]). The objectives of this study were to analyze demographic populations who self-reported having stopped smoking completely (i.e., self-reported having stopped smoking for ≥6 months in the past year as defined in previous research [6]) or tried to stop smoking, and to quantify the prevalence of the methods they used in the most recent CDC National Health Interview Survey (NHIS) data [7].

Methods

Data on methods used to stop smoking were sourced from CDC's NHIS 2022 (total survey sample size N=27,651). These data are nationally representative and have low bias [7].

The 2022 NHIS (fielded January–December 2022) asked respondents who had stopped smoking in the past two years at the time of the survey which methods they used to stop smoking completely. The 2022 survey also asked respondents who were still smoking but had tried to stop in the past one year at the time of the survey which methods they used when they tried. For easier comparison between the 'stopped smoking completely' sample (past *two* years at the time of the survey) and the 'tried' sample (past *one* year at the time of the survey), we restricted the sample of respondents who stopped smoking in the past two years to just those who stopped smoking in the past one year and who had stopped smoking for 6 months or longer at the time of the survey (i.e., those who had quit for a time 6 months $\leq t \leq 1$ year). Thus, these analyses looked at adults who stopped (N=304) or tried to stop (N=1,431) smoking in the past one year at the time of the 2022 survey. Full details of questionnaire wording are available in online supplemental materials (https://doi.org/10.17605/osf.io/HGMN6).

Although NHIS is an annual survey, other years of NHIS including the 2023 survey and previous recent NHIS questionnaires do not contain questions on methods used to stop smoking, preventing the analysis of trends across time. However, some comparisons can be made to older data in other surveys [3, 4].

The prevalence of each stop-smoking method was calculated with NHIS sampling weights to provide nationally representative population estimates. NHIS stratum and cluster variables were also used to provide 95% CIs. NHIS sampling weights were also used to produce nationally-representative weighted sample sizes, which represent estimates of the corresponding number of US adults at the population level. Demographic characteristics of the sample of adults who stopped smoking or tried to stop (sex, race or ethnicity, age, education, and sexual orientation) were derived from standard NHIS questions, similar to other CDC NHIS publications [8, 9]. Additionally, the mental health status (severity of depressive symptoms -

Patient Health Questionnaire depression scale categorization per NHIS definitions) and alcohol drinking status (current, former, or never use per NHIS definitions) of the sample of adults who stopped smoking or tried to stop were also examined.

To determine whether differences between adults who stopped smoking completely and adults who tried to stop smoking but did not stop smoking were significant statistically significant while accounting for the complex survey design, Rao-Scott chi-square tests were used with alpha = 0.05.

Among respondents who tried to stop smoking but did not stop smoking, frequency of smoking was categorized as daily ("now" smoking "every day") or non-daily ("now" smoking "some days"). The prevalence of each stop-smoking method was calculated for daily and non-daily smoking respondents separately, with Rao-Scott chi-square tests for differences between the two groups.

Only publicly available, de-identified survey data were used; therefore, this study is exempt from NIH human subjects research under NIH exemption 4 and did not require institutional review board review. These analyses were exploratory and were not preregistered.

Results

Overall Findings

Overall, an estimated 2.9 million [95% CI: 2.5 million – 3.2 million] US adults had stopped smoking in the past year and had been stopped for 6 months or longer at the time of the 2022 survey (for context, an estimated 29 million adults currently ["every day" or "some days"] smoked cigarettes at the time of the survey).

Demographic Characteristics

1.6 million [1.3 million – 1.9 million] men and 1.3 million [1.1 million – 1.5 million] women stopped smoking; most were non-Hispanic White adults, most were aged younger than 55 years, most had at least some college education, most self-identified as straight, most had none/minimal severity depressive symptoms, and most currently drank alcohol (Table 1). For reference, current alcohol use prevalence was 69.1% [68.2% – 70.0%] among the general US population in the 2022 NHIS, and 75.0% [72.6% – 77.3%] among adults who stopped or tried to stop smoking. The prevalence of none/minimal severity depressive symptoms was 78.6% [78.0% – 79.3%] among the general US population in the 2022 NHIS and 65.2% [62.6% – 67.7%] among adults who stopped or tried to stop smoking. Compared to those who tried but didn't stop smoking, those who successfully stopped were more likely to be younger, degree-educated, and gay/lesbian/bisexual, though fewer gay/lesbian/bisexual adults stopped smoking overall compared to straight adults.

Stop-Smoking Methods

Among those who stopped smoking, the most commonly reported listed methods were nicotine products (53.9%, 1.5 million US adults), primarily e-cigarettes used alone or in combination with other methods (40.8%, 1.2 million US adults; Table 2). Among those who stopped smoking using e-cigarettes, 69.3% currently used e-cigarettes (i.e. "now" used e-cigarettes "every day" or "some days"), and the remaining 30.7% formerly used e-cigarettes (i.e. "now" used e-cigarettes "not at all"). The least commonly reported listed methods were non-nicotine, non-prescription drug methods (including a quit line, counseling or clinic, class, or group; 6.3%, 0.2 million US adults). Of the listed methods, the most commonly reported exclusive method selected was e-cigarettes; 26.0% (0.7 million US adults) of adults who stopped smoking for 6 months or longer at the time of the 2022 survey selected e-cigarettes as their only listed method.

In the same period, 13.1 million [12.2 million – 14.0 million] tried to stop but were unsuccessful. Compared to those who tried but did not stop smoking, those who successfully stopped were more likely to report using e-cigarettes to stop smoking; and less likely to report using nicotine patches and prescription drugs to stop smoking.

Among those who tried but did not stop smoking, compared to those who smoked non-daily, those who smoked daily were more likely to have used one or more pharmacotherapy (nicotine products and prescription drugs) and non-nicotine, non-prescription drug methods in their attempt to stop smoking. I.e., compared to those who smoked daily, those who smoked non-daily were more likely to not have tried any of the surveyed methods when they attempted to stop smoking.

Discussion

This study analyzed populations of US adults in NHIS 2022 who stopped or tried to stop smoking and the methods they used. Approximately 29 million adults currently smoked cigarettes in 2022. The number of adults who stopped smoking completely was only one tenth of that number, and less than half of those 29 million who remained smoking tried to stop smoking (but did not stop). These findings suggest that more efforts are required to encourage adults who smoke to try to stop smoking in the first place.

46.6% of adults (including 42.5% of adults who stopped smoking and 47.5% of adults who tried but did not stop smoking) did not report using any of the surveyed evidence-based methods to stop smoking. This finding is not dissimilar to the finding in the PATH 2013–2014 data by Rodu and Plurphanswat [3], who reported that 33.5% of adults who currently smoked (and who tried to stop) and 32.8% of adults who formerly smoked reported having attempted to stop smoking completely unaided. Methods containing nicotine, primarily e-cigarettes, were the

most commonly-reported methods that were explicitly surveyed. Caraballo et al. [4] found that in 2014–2016 data, switching to e-cigarettes was reported by 35.3% of US adults who smoked cigarettes in their most recent attempt, while Rodu and Plurphanswat [3] found that in 2013–2014 data, e-cigarettes were the second most frequently used single method to stop smoking (32% of all single methods). In comparison, the present study found in 2022 data that e-cigarettes were used to stop smoking by 40.8% of adults who stopped smoking and 20.7% of adults who tried but did not stop smoking. While noting the necessity of preventing access to nicotine products by nonsmoking populations such as adolescents, the high prevalence of e-cigarette use to stop smoking in this study may provide support for FDA's "nicotine-focused framework for public health" [10], which describes noncombustible nicotine products as "a promising foundation for a comprehensive approach to tobacco harm reduction." In recent years, FDA have authorized a number of e-cigarette products as "appropriate for the protection of public health" [5]. CDC also state that "[e]-cigarettes have the potential to benefit adults who smoke . . . if used as a complete substitute for regular cigarettes" [11].

The least commonly-reported methods to stop smoking were the non-nicotine, non-prescription drug methods, including quit lines, counselling, and clinics/classes/groups. These methods were reported by just 6.3% of adults who stopped smoking and 7.9% of adults who tried but did not stop smoking. This finding is unsurprising since randomized controlled trials have consistently shown pharmacological interventions - including e-cigarettes - to be superior to non-pharmacological controls in terms of smoking abstinence efficacy [12]. While non-pharmacological methods clearly work for some adults and should not be discouraged, given the urgency of the need to reduce morbidity and mortality from cigarette smoking, it may be preferable from a public health perspective to encourage adults who smoke to try the most efficacious stop-smoking methods first.

Compared to those who tried but didn't stop smoking, those who successfully stopped were more likely to be younger, degree-educated, and gay/lesbian/bisexual, though fewer gay/lesbian/bisexual adults stopped smoking compared to straight adults. This finding highlights disparities in smoking cessation; it is important to ensure that specific demographic populations do not get left behind in efforts to curb smoking. Additionally, those who successfully stopped smoking were more likely to have used e-cigarettes to stop smoking, and were less likely to have used nicotine patches and prescription drugs to stop smoking. It is possible that these differences are mediated by demographic differences (though model-based comparisons may not be appropriate for these data due to low sample size) and by barriers to access (e.g. out-of-pocket pharmacy costs [13] and other access restrictions [14]).

This study's strengths include use of a large, nationally representative survey with low bias administered by CDC. NHIS results are thought to be generalizable to the entire US population, because that is the purpose of its sample design by CDC's National Center for Health Statistics [7, 15]. Another strength is the direct measures of stopping smoking (i.e., survey questions answered by adults who actually stopped smoking) as opposed to indirect measures of stopping smoking (e.g., models).

This study also has limitations. First is the inability to parse out individual methods in the "none of the above" category, which is an unavoidable limitation of the NHIS questionnaire design. Because "none of the above" was inferred from respondents who stopped or tried but who did not select any of the surveyed items, the "none of the above" category may be underrepresented in these analyses. Furthermore, the questionnaire did not ask respondents about the duration of treatment use. Future questionnaires should ask respondents for these details. Recall bias may also limit the accuracy of these findings [16]. Additionally, we chose to treat respondents who responded with "don't know" as missing, which has its limitations. Also

importantly, the NHIS 2022 data did not explicitly survey some of the other more recent stop-smoking methods such as nicotine pouches, snus, heat-not-burn or heated tobacco products, and others – these should also be surveyed in future questionnaires.

In conclusion, more younger adults are stopping smoking compared to older adults, which may leave the latter at risk of being 'left behind' in efforts to stop smoking. Nicotine-containing methods, especially e-cigarettes, are by far the most commonly-reported methods used to stop smoking among the evidence-based methods surveyed in NHIS. Adults who stopped smoking completely are more likely to report using e-cigarettes than those who tried but did not stop smoking. These findings may support the basis for harm reduction in tobacco control. However, many adults still attempt to stop smoking without evidence-based methods. Future efforts to reduce smoking among US adults should focus on the demographic populations that stopped smoking the least and encourage use of evidence-based methods.

Acknowledgements

An early version of this research was presented in poster form at the 2024 Society for Research on Nicotine and Tobacco (SRNT) annual meeting (https://doi.org/10.31219/osf.io/2yuw4). The authors thank anonymous reviewers and participants at the 2024 SRNT meeting for helpful comments and suggestions. F.F. thanks Mark Sembower of Pinney Associates for discussion. This work received no financial support.

Statement of Data Availability

NHIS data are publicly available at https://www.cdc.gov/nchs/nhis/index.htm

Competing Interests

The authors declare the following potential conflicts of interests:

F.F. provides consulting services through Pinney Associates on tobacco harm reduction to Juul Labs Inc, which had no involvement in this article. As of October 2024, Pinney Associates also consults to Philip Morris International solely on US regulatory pathways for non-combustible, non-tobacco, nicotine products, which also had no involvement in this article. Pinney Associates does not consult on combustible tobacco products.

R.N. has received grant and contractual funding from the National Institutes of Health and the Food and Drug Administration; served as a paid consultant to the Government of Canada via a contract with Industrial Economics Inc; received an honorarium for a virtual meeting from Pfizer Inc; received other NIDA grants paid to his employers; received salary from the Steven Schroeder Institute for Tobacco Research and Policy Studies at The Legacy Foundation, now Truth Initiative, New York University School of Global Public Health; and communicated with Juul Labs personnel, for which there was no compensation, and received hospitality in the form of meals at some meetings; none of which supported the work reported here. The Progressive Policy Institute sponsored a trip (travel and lodging) for R.N. to present a paper at a symposium: Can e-cigarettes help tobacco cigarette smokers quit? A review of the evidence, Tobacco Harm Reduction – an Update, 54th annual meeting of the Japanese Society of Neuropsychopharmacology, jointly held with the 34th annual meeting of the Japanese Society of Clinical Neuropsychopharmacology and the 35th World Congress Collegium Internationale Neuro-Psychopharmacologicum, Tokyo International Forum, Tokyo, Japan, May 24, 2024; no honorarium, consulting fee or other payment was provided.

Table 1. Demographic Characteristics of Adults Who Stopped Smoking (N = 304), or Tried to Stop Smoking but Did Not Stop Smoking (N = 1,431) in the Past Year at the Time of the Survey, National Health Interview Survey 2022[a]

Characteristic	Stopped smoking completely[b], (N = 304) Weighted % (95% CI) Weighted N in millions (95% CI) Unweighted n	Tried to stop smoking but did not stop smoking (N = 1,431) Weighted % (95% CI) Weighted N in millions (95% CI) Unweighted n	Total (stopped smoking completely or tried to stop smoking but did not stop smoking) (N = 1,735) Weighted % (95% CI) Weighted N in millions (95% CI) Unweighted n
All adults	100 2.9 (2.5–3.2) 304	100 13.1 (12.2–14.0) 1431	100 16.0 (15.0–17.0) 1735
Sex			
Female	45.3 (39.1–51.5) 1.3 (1.1–1.5) 156	44.2 (41.1–47.2) 5.8 (5.3–6.3) 687	44.4 (41.6–47.1) 7.1 (6.5–7.7) 843
Male	54.7 (48.5–60.9) 1.6 (1.3–1.9) 148	55.8 (52.8–58.9) 7.3 (6.7–7.9) 744	55.6 (52.9–58.4) 8.9 (8.2–9.6) 892
Race or ethnicity			
Hispanic	15.2 (10.8–20.6) 0.4 (0.3–0.6) 43	12.0 (9.9–14.4) 1.6 (1.3–1.9) 152	12.6 (10.6–14.9) 2.0 (1.7–2.4) 195
Non-Hispanic Black	11.2 (7.4–16.1) 0.3 (0.2–0.5) 35	16.1 (13.7–18.6) 2.1 (1.8–2.4) 247	15.2 (13.1–17.5) 2.4 (2.1–2.8) 282
Non-Hispanic White	67.3 (60.9–73.2) 1.9 (1.6–2.2) 207	65.1 (62.1–68.0) 8.5 (7.9–9.2) 937	65.5 (62.7–68.1) 10.5 (9.7–11.2) 1144
Non-Hispanic Other	6.3 (3.5–10.3) 0.2 (0.1–0.3) 19	6.8 (5.4–8.6) 0.9 (0.7–1.1) 95	6.7 (5.4–8.3) 1.1 (0.8–1.3) 114
Age (Years)*			
18–34	41.9 (35.3–48.8) 1.2 (1.0–1.4) 111	24.7 (21.9–27.6) 3.2 (2.8–3.7) 268	27.8 (25.2–30.5) 4.4 (3.9–5.0) 379
35–54	34.2 (27.9–40.9) 1.0 (0.8–1.2) 102	39.6 (36.4–42.8) 5.2 (4.7–5.7) 512	38.6 (35.8–41.4) 6.2 (5.6–6.8) 614
55 or older	23.9 (18.8–29.6) 0.7 (0.5–0.9) 91	35.7 (33.0–38.6) 4.7 (4.3–5.1) 651	33.6 (31.1–36.2) 5.4 (4.9–5.9) 742
Education*			
≤12 years (no diploma)	9.4 (5.9–14.1) 0.3 (0.1–0.4) 27	18.5 (16.0–21.3) 2.4 (2.0–2.8) 220	16.9 (14.7–19.3) 2.7 (2.3–3.1) 247

GED certificate or high school diploma	34.4 (28.5–40.7) 1.0 (0.8–1.2) 95	38.5 (35.5–41.7) 5.0 (4.5–5.5) 519	37.8 (35.0–40.7) 6.0 (5.4–6.5) 614
Some college (no degree)	18.8 (14.4–23.9) 0.5 (0.4–0.7) 61	17.1 (15.1–19.3) 2.2 (1.9–2.5) 258	17.4 (15.6–19.4) 2.8 (2.4–3.1) 319
Associate, undergraduate, or graduate degree	37.3 (31.1–43.9) 1.1 (0.8–1.3) 117	25.8 (23.2–28.5) 3.4 (2.9–3.8) 426	27.9 (25.4–30.4) 4.4 (4.0–4.9) 543
Sexual orientation*			
Gay/lesbian/bisexual	12.8 (8.7–17.9) 0.4 (0.2–0.5) 37	5.8 (4.5–7.4) 0.8 (0.6–1.0) 82	7.1 (5.7–8.6) 1.1 (0.9–1.4) 119
Straight	82.8 (76.8–87.8) 2.4 (2.0–2.7) 254	90.0 (88.1–91.7) 11.8 (11.0–12.6) 1293	88.7 (86.9–90.4) 14.2 (13.3–15.1) 1547
Other	4.4 (1.8–8.7) 0.1 (0.0–0.2) 13	4.1 (3.0–5.6) 0.5 (0.4–0.7) 56	4.2 (3.1–5.5) 0.7 (0.5–0.9) 69
Severity of depressive symptoms - Patient Health Questionnaire depression scale categorization			
None/Minimal	63.7 (57.1–70.1) 1.8 (1.5–2.1) 191	65.5 (62.6–68.3) 8.6 (7.9–9.3) 922	65.2 (62.6–67.7) 10.4 (9.6–11.2) 1113
Mild	20.7 (15.8–26.4) 0.6 (0.4–0.7) 64	19.5 (17.2–22.0) 2.6 (2.2–2.9) 278	19.7 (17.6–21.9) 3.1 (2.8–3.5) 342
Moderate	7.7 (4.8–11.5) 0.2 (0.1–0.3) 27	8.3 (6.8–10.0) 1.1 (0.9–1.3) 128	8.2 (6.8–9.7) 1.3 (1.1–1.5) 155
Severe	7.9 (4.7–12.3) 0.2 (0.1–0.3) 20	6.7 (5.2–8.5) 0.9 (0.7–1.1) 100	6.9 (5.5–8.6) 1.1 (0.9–1.3) 120
Alcohol drinking status			
Current	80.1 (74.5–84.9) 2.3 (1.9–2.6) 231	73.9 (71.2–76.5) 9.5 (8.7–10.2) 1000	75.0 (72.6–77.3) 11.7 (10.9–12.6) 1231
Former	16.6 (12.2–21.8) 0.5 (0.3–0.6) 58	21.0 (18.6–23.6) 2.7 (2.4–3.0) 332	20.2 (18.1–22.5) 3.2 (2.8–3.5) 390
Never	3.3 (1.4–6.6) 0.1 (0.0–0.2) 10	5.1 (3.8–6.6) 0.6 (0.5–0.8) 72	4.7 (3.6–6.1) 0.7 (0.5–0.9) 82

* Indicates a statistically significant difference between adults who stopped smoking completely and adults who tried to stop smoking but did not stop smoking (Rao-Scott chi-square test; $p<0.05$).

[a] Following Cornelius et al. [8], modified Clopper-Pearson confidence limits for percentages were calculated by using the Korn and Graubard method.

[b] Reported having stopped smoking for 6 months or longer in the past year, as defined in previous research [6].

Table 2. Methods Used by Adults Who Stopped Smoking (N = 304), or Tried to Stop Smoking but Did Not Stop Smoking (N = 1,431) in the Past Year at the Time of the Survey, National Health Interview Survey, 2022[a]

Method(s)	Stopped smoking completely[b], (N = 304) Weighted % (95% CI) Weighted N in millions (95% CI) Unweighted n	Tried to stop smoking but did not stop smoking (N = 1,431) Weighted % (95% CI) Weighted N in millions (95% CI) Unweighted n	Total (stopped smoking completely or tried to stop smoking but did not stop smoking) (N = 1,735) Weighted % (95% CI) Weighted N in millions (95% CI) Unweighted n
Any method	100 2.9 (2.5–3.2) 304	100 13.1 (12.2–14.0) 1431	100 16.0 (15.0–17.0) 1735
Nicotine products			
E-cigarettes*	40.8 (34.4–47.5) 1.2 (0.9–1.4) 111	20.7 (18.1–23.4) 2.7 (2.3–3.1) 262	24.3 (21.9–26.8) 3.9 (3.4–4.4) 373
Exclusively*[c]	26.0 (20.4–32.3) 0.7 (0.6–0.9) 71	11.2 (9.3–13.3) 1.5 (1.2–1.7) 139	13.8 (11.9–15.9) 2.2 (1.9–2.6) 210
Nicotine gum/lozenge	18.8 (14.1–24.4) 0.5 (0.4–0.7) 56	19.0 (16.7–21.4) 2.5 (2.1–2.9) 281	18.9 (16.8–21.2) 3.0 (2.6–3.4) 337
Exclusively[c]	—[d]	4.8 (3.7–6.2) 0.6 (0.5–0.8) 69	4.5 (3.4–5.7) 0.7 (0.5–0.9) 77
Nicotine patch*	15.4 (11.1–20.6) 0.4 (0.3–0.6) 51	22.1 (19.7–24.6) 2.9 (2.5–3.3) 346	20.9 (18.8–23.1) 3.3 (2.9–3.8) 397
Exclusively[c]	5.4 (2.8–9.4) 0.2 (0.1–0.2) 15	7.4 (6.1–9.0) 1.0 (0.8–1.2) 114	7.1 (5.8–8.5) 1.1 (0.9–1.4) 129
Nicotine nasal spray/inhaler	—[d]	0.9 (0.5–1.7) 0.1 (0.0–0.2) 18	0.9 (0.5–1.5) 0.1 (0.1–0.2) 23
Exclusively[c]	—[d]	—[d]	—[d]
One or more nicotine product(s)*	53.9 (47.4–60.3) 1.5 (1.3–1.8) 157	45.1 (42.0–48.2) 5.9 (5.3–6.5) 645	46.6 (43.8–49.5) 7.5 (6.8–8.1) 802
Prescription drug products			
Varenicline*	5.1 (2.9–8.2) 0.1 (0.1–0.2) 18	11.3 (9.5–13.3) 1.5 (1.2–1.7) 170	10.2 (8.6–11.8) 1.6 (1.4–1.9) 188
Exclusively[c]	—[d]	3.0 (2.1–4.2) 0.4 (0.3–0.5) 45	2.8 (2.0–3.7) 0.4 (0.3–0.6) 51
Bupropion	4.7 (2.6–7.7) 0.1 (0.1–0.2) 17	7.4 (5.9–9.0) 1.0 (0.8–1.2) 114	6.9 (5.6–8.3) 1.1 (0.9–1.3) 131

Exclusively[c]	—[d]	1.7 (1.0–2.7) 0.2 (0.1–0.3) 29	1.5 (0.9–2.2) 0.2 (0.1–0.3) 30
One or more prescription drug product(s)*	8.1 (5.3–11.8) 0.2 (0.1–0.3) 30	16.2 (14.2–18.5) 2.1 (1.8–2.4) 244	14.8 (13.0–16.7) 2.4 (2.0–2.7) 274
One or more pharmacotherapy (nicotine product incl. e-cigarettes or prescription drug product)	56.6 (49.9–63.1) 1.6 (1.3–1.9) 168	51.1 (47.9–54.3) 6.7 (6.1–7.3) 739	52.1 (49.2–55.0) 8.3 (7.6–9.0) 907
Non-nicotine, non-prescription drug methods			
Quit line	3.1 (1.4–5.7) 0.1 (0.0–0.1) 12	4.3 (3.2–5.7) 0.6 (0.4–0.7) 74	4.1 (3.1–5.3) 0.7 (0.5–0.8) 86
Exclusively[c]	—[d]	—[d]	—[d]
Counseling	3.1 (1.5–5.7) 0.1 (0.0–0.1) 14	4.8 (3.6–6.2) 0.6 (0.5–0.8) 78	4.5 (3.5–5.7) 0.7 (0.5–0.9) 92
Exclusively[c]	—[d]	0.6 (0.3–1.2) 0.1 (0.0–0.1) 12	0.5 (0.2–1.0) 0.1 (0.0–0.1) 13
Clinic/class/group	—[d]	2.5 (1.7–3.5) 0.3 (0.2–0.4) 40	2.4 (1.7–3.3) 0.4 (0.3–0.5) 48
Exclusively[c]	—[d]	—[d]	—[d]
One or more non-nicotine, non-prescription drug method(s)	6.3 (3.9–9.7) 0.2 (0.1–0.3) 26	7.9 (6.4–9.7) 1.0 (0.8–1.3) 133	7.6 (6.3–9.2) 1.2 (1.0–1.5) 159
Any of the above[e]	57.5 (50.8–63.9) 1.6 (1.4–1.9) 172	52.5 (49.2–55.7) 6.9 (6.3–7.5) 765	53.4 (50.5–56.2) 8.5 (7.9–9.2) 937
None of the above[f]	42.5 (36.1–49.2) 1.2 (1.0–1.5) 132	47.5 (44.3–50.8) 6.2 (5.7–6.8) 666	46.6 (43.8–49.6) 7.5 (6.8–8.1) 798

* Indicates a statistically significant difference between adults who stopped smoking completely and adults who tried to stop smoking but did not stop smoking (Rao-Scott chi-square test; $p<0.05$).

[a] Following Cornelius et al. [9], modified Clopper-Pearson confidence limits for percentages were calculated by using the Korn and Graubard method.

[b] Reported having stopped smoking for 6 months or longer in the past year, as defined in previous research [6].

[c] Exclusive percentages are expressed among all adults who stopped or tried to stop smoking, not as a percentage of those adults who used the particular method (e.g., 26.0% of all adults who stopped smoking used e-cigarettes exclusively). Exclusive means the respondent selected that particular method but did not select the other methods listed on the questionnaire (e.g., exclusive e-cigarette means reported using e-cigarettes but not nicotine gum or lozenge, nicotine patch, nicotine nasal spray/inhaler, varenicline, bupropion, a quit line, counseling, or clinic/class/group).

[d] Estimates with an unweighted denominator or numerator less than 10, relative 95% CI width >160%, or degrees of freedom less than 8 are suppressed, consistent with the latest 2023 National Center for Health Statistics standards for rates and counts [17].

[e] Stopped smoking "completely" or tried in the past year at the time of the 2022 survey and reported using any of e-cigarettes, nicotine gum/lozenge, nicotine patch, nicotine nasal spray/inhaler, varenicline, bupropion, quit line, counseling, or clinic/class/group.

[f] Stopped smoking "completely" or tried in the past year at the time of the 2022 survey but did not report using any of e-cigarettes, nicotine gum/lozenge, nicotine patch, nicotine nasal spray/inhaler, varenicline, bupropion, quit line, counseling, or clinic/class/group.

Table 3. Methods Used by Adults Who Tried to Stop Smoking but Did Not Stop Smoking (N = 1,431) in the Past Year at the Time of the Survey by Smoking Frequency, National Health Interview Survey, 2022[a]

Method(s)	Daily Smoking[b], (N = 990) Weighted % (95% CI) Weighted N in millions (95% CI) Unweighted n	Non-Daily Smoking[b] (N = 441) Weighted % (95% CI) Weighted N in millions (95% CI) Unweighted n
Any method	100 8.9 (8.2–9.6) 990	100 4.2 (3.7–4.7) 441
Nicotine products		
E-cigarettes	19.7 (16.6–23.1) 1.8 (1.4–2.1) 180	22.8 (18.0–28.2) 1.0 (0.7–1.2) 82
Exclusively*[c]	9.5 (7.3–12.1) 0.8 (0.6–1.1) 87	14.6 (10.7–19.4) 0.6 (0.4–0.8) 52
Nicotine gum/lozenge*	21.5 (18.6–24.6) 1.9 (1.6–2.2) 222	13.7 (10.3–17.7) 0.6 (0.4–0.7) 59
Exclusively[c]	4.8 (3.5–6.4) 0.4 (0.3–0.6) 52	4.8 (2.6–8.1) 0.2 (0.1–0.3) 17
Nicotine patch*	25.8 (22.8–28.9) 2.3 (2.0–2.6) 272	14.4 (10.9–18.5) 0.6 (0.4–0.8) 74
Exclusively*[c]	9.1 (7.3–11.3) 0.8 (0.6–1.0) 91	3.8 (2.2–6.1) 0.2 (0.1–0.2) 23
Nicotine nasal spray/inhaler	—[d]	—[d]
Exclusively[c]	—[d]	—[d]
One or more nicotine product(s)*	47.8 (44.0–51.6) 4.3 (3.8–4.8) 482	39.3 (33.7–45.2) 1.7 (1.3–2.0) 163
Prescription drug products		
Varenicline*	12.8 (10.4–15.4) 1.1 (0.9–1.4) 131	8.1 (5.5–11.4) 0.3 (0.2–0.5) 39
Exclusively[c]	3.3 (2.1–4.8) 0.3 (0.2–0.4) 32	2.6 (1.3–4.7) 0.1 (0.0–0.2) 13
Bupropion*	8.7 (6.8–11.0) 0.8 (0.6–1.0) 90	4.4 (2.7–6.9) 0.2 (0.1–0.3) 24
Exclusively[c]	2.0 (1.1–3.3) 0.2 (0.1–0.3) 20	—[d]
One or more prescription drug product(s)*	18.5 (15.8–21.5) 1.7 (1.4–1.9) 188	11.4 (8.4–15.0) 0.5 (0.3–0.6) 56

One or more pharmacotherapy (nicotine product incl. e-cigarettes or prescription drug product)*	54.9 (50.9–58.7) 4.9 (4.4–5.4) 554	43.2 (37.4–49.1) 1.8 (1.5–2.1) 185
Non-nicotine, non-prescription drug methods		
Quit line*	5.2 (3.7–7.0) 0.5 (0.3–0.6) 61	2.6 (1.2–4.7) 0.1 (0.0–0.2) 13
Exclusively[c]	—[d]	—[d]
Counseling*	5.6 (4.1–7.4) 0.5 (0.4–0.6) 63	3.0 (1.5–5.3) 0.1 (0.0–0.2) 15
Exclusively[c]	—[d]	—[d]
Clinic/class/group	2.8 (1.8–4.1) 0.2 (0.1–0.3) 32	—[d]
Exclusively[c]	—[d]	—[d]
One or more non-nicotine, non-prescription drug method(s)*	9.4 (7.4–11.8) 0.8 (0.6–1.0) 108	4.8 (2.9–7.3) 0.2 (0.1–0.3) 25
Any of the above*[e]	56.5 (52.5–60.4) 5.0 (4.5–5.6) 575	44.0 (38.2–49.9) 1.9 (1.5–2.2) 190
None of the above*[f]	43.5 (39.6–47.5) 3.9 (3.4–4.3) 415	56.0 (50.1–61.8) 2.4 (2.0–2.7) 251

* Indicates a statistically significant difference between adults who smoked daily and adults who smoked non-daily (Rao-Scott chi-square test; $p<0.05$).

[a] Following Cornelius et al. [9], modified Clopper-Pearson confidence limits for percentages were calculated by using the Korn and Graubard method.

[b] Daily smoking is defined as having ever smoked 100 cigarettes (lifetime) and “now” smoking cigarettes “every day”. Non-daily smoking is defined as having ever smoked 100 cigarettes (lifetime) and “now” smoking cigarettes “some days”.

[c] Exclusive percentages are expressed among all adults who tried to stop smoking, not as a percentage of those adults who used the particular method. Exclusive means the respondent selected that particular method but did not select the other methods listed on the questionnaire (e.g., exclusive e-cigarette means reported using e-cigarettes but not nicotine gum or lozenge, nicotine patch, nicotine nasal spray/inhaler, varenicline, bupropion, a quit line, counseling, or clinic/class/group).

[d] Estimates with an unweighted denominator or numerator less than 10, relative 95% CI width >160%, or degrees of freedom less than 8 are suppressed, consistent with the latest 2023 National Center for Health Statistics standards for rates and counts [17].

[e] Tried to stop smoking in the past year at the time of the 2022 survey and reported using any of e-cigarettes, nicotine gum/lozenge, nicotine patch, nicotine nasal spray/inhaler, varenicline, bupropion, quit line, counseling, or clinic/class/group.

[f] Tried to stop smoking in the past year at the time of the 2022 survey but did not report using any of e-cigarettes, nicotine gum/lozenge, nicotine patch, nicotine nasal spray/inhaler, varenicline, bupropion, quit line, counseling, or clinic/class/group.

References

1. Levy DT, Sánchez-Romero LM, Travis N, Yuan Z, Li Y, Skolnick S, Jeon J, Tam J, Meza R: **US Nicotine Vaping Product SimSmoke Simulation Model: The Effect of Vaping and Tobacco Control Policies on Smoking Prevalence and Smoking-Attributable Deaths**. *International Journal of Environmental Research and Public Health* 2021, **18**(9):4876.
2. GBD 2019 Risk Factors Collaborators: **Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019**. *The Lancet* 2020, **396**(10258):1223-1249.
3. Rodu B, Plurphanswat N: **Quit Methods Used by American Smokers, 2013–2014**. *International Journal of Environmental Research and Public Health* 2017, **14**(11):1403.
4. Caraballo RS, Shafer PR, Patel D, Davis KC, McAfee TA: **Quit methods used by US adult cigarette smokers, 2014–2016**. *Preventing chronic disease* 2017, **14**.
5. **Premarket tobacco product marketing granted orders** [https://www.fda.gov/tobacco-products/premarket-tobacco-product-applications/premarket-tobacco-product-marketing-granted-orders]
6. Walton K, Wang TW, Prutzman Y, Jamal A, Babb SD: **Characteristics and Correlates of Recent Successful Cessation Among Adult Cigarette Smokers, United States, 2018**. *Preventing chronic disease* 2020, **17**.
7. Zablotsky B, Lessem SE, Gindi RM, Maitland AK, Dahlhamer JM, Blumberg SJ: **Overview of the 2019 National Health Interview Survey Questionnaire Redesign**. *American Journal of Public Health* 2023, **113**(4):408-415.
8. Cornelius ME: **Tobacco product use among adults—United States, 2019**. *MMWR Morbidity and mortality weekly report* 2020, **69**.
9. Cornelius ME: **Tobacco product use among adults—United States, 2020**. *MMWR Morbidity and mortality weekly report* 2022, **71**.

10. Gottlieb S, Zeller M: **A Nicotine-Focused Framework for Public Health**. *New England Journal of Medicine* 2017, **377**(12):1111-1114.

11. **About electronic cigarettes (e-cigarettes)** [https://web.archive.org/web/20240102195530/https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html]

12. Lindson N, Theodoulou A, Ordóñez-Mena JM, Fanshawe TR, Sutton AJ, Livingstone-Banks J, Hajizadeh A, Zhu S, Aveyard P, Freeman SC *et al*: **Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses**. *Cochrane Database Syst Rev* 2023, **9**(9):Cd015226.

13. Suehs BT, Davis C, Galaznik A, Joshi AV, Zou KH, Patel NC: **Association of Out-of-Pocket Pharmacy Costs with Adherence to Varenicline**. *Journal of Managed Care Pharmacy* 2014, **20**(6):592-600.

14. Galaznik A, Cappell K, Montejano L, Makinson G, Zou KH, Lenhart G: **Impact of access restrictions on varenicline utilization**. *Expert Review of Pharmacoeconomics & Outcomes Research* 2013, **13**(5):651-656.

15. US Centers for Disease Control and Prevention, US Department of Health and Human Services, Division of Health Interview Statistics, National Center for Health Statistics: **National Health Interview Survey 2022 survey description**. In.; 2023.

16. Borland R, Partos TR, Cummings KM: **Systematic Biases in Cross-sectional Community Studies may Underestimate the Effectiveness of Stop-Smoking Medications**. *Nicotine & Tobacco Research* 2012, **14**(12):1483-1487.

17. Parker JD, Talih M, Irimata KE, Zhang G, Branum AM, Davis D: **National Center for Health Statistics data presentation standards for rates and counts**. *Vital Health Stat* 2023, **2**(200).